

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Applicant : Bernard BIHAIN, et al.

Appl. No. : 10/072,159

Filed : February 5, 2002

Title : LIPOPROTEIN-REGULATING MEDICAMENTS

Grp./A.U. : 1656

Examiner : Unassigned

Honorable Commissioner of Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant submits the references listed on the attached forms PTO/SB/08A and 08B (sheets 1 – 10). I, the undersigned, hereby certify that the items of information contained in this statement were cited, and are listed as references in the Applicant's parent application, Serial No. 09/485,316, filed August 6, 1998 (now U.S. Patent No. 6,344,441, issued February 5, 2002). For this reason, copies of the cited references are not enclosed. This statement is being filed before the receipt of a first Office Action on the merits.

The Commissioner is hereby authorized to charge any fees in connection with this document to our Deposit Account No.: 50-1181

Respectfully submitted,

GENSET CORPORATION

Date: 5/31, 2002

By:

John Lucas
John Lucas, Ph.D., J.D.
Registration No. 43,373

10665 Sorrento Valley Road
San Diego, CA 92121-1609

Telephone: (858) 597-2600
Facsimile: (858) 597-2601

e-mail: john.lucas@genxy.com

Certificate of Mailing under 37 CFR 1.10

Date of Deposit: May 31, 2002
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, on the Date of Deposit shown above, postage prepaid and in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Signature

C H McClure
Typed or Printed Name of Person Signing Certificate

+

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet 1 of 10

Complete if Known

Application Number	10/072,159
Filing Date	February 5, 2002
First Named Inventor	Bernard BIHAIN, et al.
Group Art Unit	1656
Examiner Name	Unassigned
Attorney Docket Number	29.US4.DIV



U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials ²	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
		Office ³	Number ⁴	Kind Code ⁵ (If Known)				
	B	EP	1033134	A1	Otsuka Pharmaceutical Co. Ltd.	09/06/2000		
	C	WO	96/30400	A1	Tanox Biosystems	10/03/1996		
	D	WO	96/34981	A2	Genset	11/07/1996		
	E	WO	96/39429	A2	Whitehead Institute	12/12/1996		
	F	WO	97/27286	A1	Progenitor, Inc.	07/1997		
	G	WO	98/01257	A2	H. Federhenn	01/15/1998		
	H	WO	98/20165	A2	Whitehead Institute	05/14/1998		
	I	WO	98/54311	A1	The Scripps Research Institute	12/03/1998		
	J	WO	99/07736	A2	Genset	02/18/1999		
	K	WO	99/10492	A1	Zymogenetics, Inc.	03/04/1999		

Examiner
Signature

Date	
Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.


Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/072,159	
			Filing Date	February 5, 2002	
			First Named Inventor	Bernard BIHAIN, et al.	
			Group Art Unit	1656	
			Examiner Name	Unassigned	
			Attorney Docket Number	29.US4.DIV	
Sheet	2	of	10		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	L	Alexeev and Yoon, "STABLE AND INHERITABLE CHANGES IN GENOTYPE AND PHENOTYPE OF ALBINO MELANOCYTES INDUCED BY AN RNA-DNA OLIGONUCLEOTIDE"; Nature Biotech., 16:1343-1346, 1998		
	M	Arita, et al., "PARADOXICAL DECREASE OF AN ADIPOSE-SPECIFIC PROTEIN, ADIPONECTIN, IN OBESITY"; Biochem. and Biophys. Research Comm. 257:79-83, 1999 (Academic Press)		
	N	Costet, P., et al., "PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR α -ISOFORM DEFICIENCY LEADS TO PROGRESSIVE DYSLIPIDEMIA WITH SEXUALLY DIMORPHIC OBESITY AND STEATOSIS"; J. Biol. Chem., Vol. 273, No. 45, 29577-29585, Nov. 6, 1998 (The American Society for Biochemistry and Molecular Biology, Inc.)		
	O	Imagawa, et al., "STRUCTURE-FUNCTION STUDIES OF HUMAN LEPTIN"; J. Biol. Chem., Vol. 273, No. 52:35245-35249, December 25, 1998 (The American Society for Biochemistry and Molecular Biology, Inc.)		
	P	Kersten, S., et al., "PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR α MEDIATES THE ADAPTIVE RESPONSE TO FASTING"; J. Clin. Invest., Vol. 103, No. 11:1489-1498, June 1999 (The American Society for Clinical Investigations)		
	Q	Groenen, et al., "Structure, sequence and chromosome 19 localization of human USF2 and its rearrangement in a patient with multicystic renal adysplasia"; Genomics 38:141-148 (1995), XP002067467.		
	R	Saito, et al., "ORGANIZATION OF THE GENE FOR GELATIN-BINDING PROTEIN (GBP28)", GENE, 229:67-73, Jan. 12, 1999 (Elsevier Science B.V.)		
	S	Schaffler, et al., "THE HUMAN α M-1, AN ADIPOCYTE-SPECIFIC GENE LINKED TO THE FAMILY OF TNF'S AND TO GENES EXPRESSED IN ACTIVATED T CELLS, IS MAPPED TO CHROMOSOME 1q21.3-q23, A SUSCEPTIBILITY LOCUS IDENTIFIED FOR FAMILIA COMBINED HYPERLIPIDAEMIA (FCH)"; Biochem. and Biophys. Res. Comm. 260:416-425, May 7, 1999 (Academic Press)		
	T	Shimomura, et al., "LEPTIN REVERSES INSULIN RESISTANCE AND DIABETES MELLITUS IN MICE WITH CONGENITAL LIPODYSTROPHY"; Nature, 401:73-76, Sept. 2, 1999		
	U	Uotani, S., "FUNCTIONAL PROPERTIES OF LEPTIN RECEPTOR ISOFORMS INTERNALIZATION AND EDGRADATION OF LEPTIN AND LEGAND-INDUCED RECEPTOR DOWNREGULATION DIABETES", 48:279-286, Feb. 1999		
	V	Vansant, G., et al., "DETERMINANTS OF POSTPRANDIAL LIPERNIA IN OBESE WOMEN"; Intl. Jr. of Obesity, 23:Supp. 1, 14-21, 1999 (Stockton Press)		

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/072,159
		Filing Date	February 5, 2002
		First Named Inventor	Bernard BIHAIN, et al.
		Group Art Unit	1656
		Examiner Name	Unassigned
		Attorney Docket Number	29.US4.DIV
Sheet	3	of	10

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	W	Yen, et al., "MOLECULAR CLONING OF A LIPOLYSIS-STIMULATED REMNANT RECEPTOR EXPRESSED IN THE LIVER", J. Biol. Chem., Vol. 274, #19:13390-13398, 1999 (The American Society for Biochemistry and Molecular Biology, Inc.)	
	X	Barsh, G., et al., "GENETICS OF BODY-WEIGHT REGULATION", Nature, Vol. 404:644-651, April 6, 2000	
	Y	Friedman, J.M., "OBESITY IN THE NEW MILLENNIUM", Nature, Vol. 404:632-634, April 6, 2000 (Macmillan Magazines Ltd.)	
	Z	Oksana, G., et al., "HORMONES: LEPTIN AND DIABETES IN LIPOATROPHIC MICE", Nature, Vol. 403:850, February 24, 2000 (Macmillan Publishers Ltd.)	
	AA	Oksana, G., et al., "LACK OF RESPONSES TO A [[BETA] SUB.3]-ADRENERGIC AGONIST IN LIPOATROPHIC A-ZIP MICE", Diabetes, Vol. 49, #11:1910, Nov. 2000 (American Diabetes Association)	
	AB	Hotta, K., et al., "PLASMA CONCENTRATIONS FO A NOVEL, ADIPOSE-SPECIFIC PROTEIN, ADIPONECTIN, IN TYPE 2 DIABETIC PATIENTS", Arterioscler Thromb Vasc Biol., 1595-1599, June 2000 (American Heart Association, Inc.)	
	AC	Kishore, U., et al., "MODULAR ORGANIZATION OF PROTEINS CONTAINING Clq-like GLOBULAR DOMAIN", Immunopharmacology 42 (1999) 15-21 (1999 Elsevier Science B.V.)	
	AD	Kishor, U., et al., "Clq: STRUCTURE, FUNCTION, AND RECEPTORS", Immunopharmacology 49 (2000) 159-170 (2000 Elsevier Science B.V.)	
	AE	Kopelman, P., "OBESITY AS A MEDICAL PROBLEM", Nature, Vol. 404:635-643, April 6, 2000 (Macmillan Magazines Ltd.)	
	AF	Mann, C., et al., "INHIBITORY EFFECTS OF SPECIFIC APOLIPOPROTEIN C-III ISOFORMS ON THE BINDING OF TRIGLYCERIDE-RICH LIPOPROTEINS TO THE LIPOLYSIS-STIMULATED RECEPTOR", The Journal of Biological Chemistry, Vol. 272, #50:31348-31354, 1997 (The American Society for Biochemistry and Molecular Biology, Inc.)	
	AG	Nakano, Y., et al., "ISOLATION AND CHARACTERIZATION OF GBP28, A NOVEL GELATIN-BINDING PROTEIN PURIFIED FROM HUMAN PLASMA", J. Biochem, Vol. 120, #4:803-812 (1996)	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 10

Complete if Known

Application Number	10/072,159
Filing Date	February 5, 2002
First Named Inventor	Bernard BIHAIN, et al.
Group Art Unit	1656
Examiner Name	Unassigned
Attorney Docket Number	29.US4.DIV

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AH	Okamoto, Y., et al., "AN ADIPOCYTE-DERIVED PLASMA PROTEIN, ADIPONECTIN, ADHERES TO INJURED VASCULAR WALLS", Horm Metab Res 2000; 32:47-50 (Georg Thieme Verlag Stuttgart-New York)	
	AI	Ouchi, N., et al., "NOVEL MODULATOR FOR ENDOTHELIAL ADHESION MOLECULES / ADIPOCYTE-DERIVED PLASMA PROTEIN ADIPONECTIN", Circulation, Vol. 100:2473-2476, December 21/28, 1999 (American Heart Association)	
	AJ	Saito, K., et al., "REGULATION OF GELATIN-BINDING PROTEIN 28 (GBP28) GENE EXPRESSION BY C/EBP", Biol. Pharm. Bull. 22(11) 1158-1162 (1999)	
	AK	Shapiro, L., et al., "THE CRYSTAL STRUCTURE OF A COMPLEMENT-1q FAMILY PROTEIN SUGGESTS AN EVOLUTIONARY LINK TO TUMOR NECROSIS FACTOR", Current Biology, Vol. 8, No. 6, pp. 335-338	
	AL	Takahashi, M., et al., "GENOMIC STRUCTURE AND MUTATIONS IN ADIPOSE-SPECIFIC GENE, ADIPONECTIN", International Journal of Obesity (2000) 24, 861-868 (Macmillan Publishers Ltd.)	
	AM	Yokota, T., et al., "ADIPONECTIN, A NEW MEMBER OF THE FAMILY OF SOLUBLE DEFENSE COLLAGENS, NEGATIVELY REGULATES THE GROWTH OF MYELOMONOCYTIC PROGENITORS AND THE FUNCTIONS OF MACROPHAGES", Blood, September 1, 2000 - Vol. 96, No. 5, pp. 1723-1732 (The American Society of Hematology)	
	AN	Bihain, B., et al., "THE LIPOLYSIS-STIMULATED RECEPTOR: A GENE AT LAST", Current Opinion in Lipodology, Vol. 9, no. 3, pp. 221-224, June 1998.	
	AH	Groenen, P. et al., "STRUCTURE, SEQUENCE AND CHROMOSOME 19 LOCATION OF HUMAN USF2...", EMBL Sequence Database, 24 January 1997, XP002067467.	
	AO	Lamerdin, J.E., "HOMO SAPIENS DNA FROM CHROMOSOME 19-COSMID R30879 CONTAINING USF2, GENOMIC SEQUENCE", EMBL Sequence Database, 26 March 1997, XP002096567.	
	AP	Lamerdin, J.E. et al., "SEQUENCE ANALYSIS OF A 1 MB REGION OF HUMAN 19Q13.1", EMBL Sequence Database, 28 May 1997, XP002096568.	
	AQ	Lamerdin, J.E., et al., "HUMAN LISCH7", EMBL Sequence Database, 1 July 1997, XP002096569.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/072,159
			Filing Date	February 5, 2002
			First Named Inventor	Bernard BIHAIN, et al.
			Group Art Unit	1656
			Examiner Name	Unassigned
			Attorney Docket Number	29.US4.DIV
Sheet	5	of	10	


OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AR	Lamerdin, J.E., et al., "LIVER-SPECIFIC BHLF-ZIP TRANSCRIPTION FACTOR, LISCH7", EMBL Sequence Database, 1 July 1997, XP002096570.	
	AS	Lin, Q., et al., "LISCH7, A LIVER-SPECIFIC GENE IMMEDIATELY UPSTREAM OF THE USF2 GENE ON CHROMOSOME 7", EMBL Sequence Database, 20 May 1996, XP002096565.	
	AT	Lin, Q., et al., "LIVER-SPECIFIC PROTEIN LISCH7", EMBL Sequence Database, 1 November 1996, XP002096566.	
	AU	Austin, et al.; "Hypertriglyceridemia as a Cardiovascular Risk Factor," Am. J. Cardiol., 81:7B-12B (1998)	
	AV	Baldo, et al.; "The Adipsin-Acylation Stimulating Protein System and Regulation of Intracellular Triglyceride Synthesis," J. Clin. Invest., 92:1543-1547 (1993)	
	AW	Bartles, J.R., et al.; "Biogenesis of the Rat Hepatocyte Plasma Membrane," Methods Enzymol., 191:825-841 (1990)	
	AX	Bihain, B.E., et al.; "Characterization and purification of the lipolysis-stimulated receptor," Elsevier Science B.V., pp. 465-470 (1995)	
	AY	Bihain, B.E., et al.; "Free Fatty Acids Activate a High-Affinity Saturable Pathway for Degradation of Low-Density Lipoproteins in Fibroblasts from a Subject Homozygous for Familial Hypercholesterolemia", Biochemistry, 31:4628-4636 (1992)	
	AZ	Brendel, V., et al.; "Methods and Algorithms for statistical analysis of protein sequences," Proc. Natl. Acad. Sci. USA, 89:2002-2006 (1992)	
	BA	Chen, W.J., et al., "NPXY, a Sequence often Found in Cytoplasmic Tails, is Required for Coated Pit-Mediated Internalization of the Low Density Lipoprotein Receptor", J. Biol. Chem., 265:3116-3123 (1990)	
	BB	Cole-Strauss, et al.; "Correction of the Mutation Responsible for Sickle Cell Anemia by an RNA-DNA Oligonucleotide," Science, 273:1386-1389 (1996)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Application Number	10/072.159
			Filing Date	February 5, 2002
			First Named Inventor	Bernard BIHAIN, et al.
			Group Art Unit	1656
			Examiner Name	Unassigned
			Attorney Docket Number	29.US4.DIV
Sheet	6	of	10	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	BC	Davis, C.G., et al.; "The J.D. Mutation in Familial Hyper-cholesterolemia: Amino Acid Substitution in Cytoplasmic Domain Impedes Internalization of LDL Receptors," Cell, 45:15-24, 1986	
	BD	Dietrich, J., et al.; "CD3 (Contains a Phosphoserine-Dependent D8-Leucine Motif Involved in Down-Regulation of the T Cell Receptor," EMBO Journal 13:2156-2166 (1994)	
	BE	Everhart, J.E., "Weight Change and Obesity after Liver Transplantation: Incidence and Risk Factors," Liver Transpl. Surg., 4:285-296 (1998)	
	BF	Feeman, Jr., W.E., "Hypertriglyceridemia and Atherosclerosis," Annals of Internal Medicine, Vol. 128, No. 1, pp. 73-74 (1998)	
	BG	Ghebrehiwet, et al., "Isolation, cDNA Cloning, and Overexpression of a 33-kD Cell Surface Glycoprotein that Binds to the Globular "Heads" of Clq"; J. Exp. Med., 179:1809-1821 (1994)	
	BH	Goldstein, J.L., et al., "Familial Hypercholesterolemia"; The Metabolic and Molecular Bases of Inherited Disease, Vol. 11, 7th Ed. (Scriver, C.R., et al., ed); McGraw-Hill, New York, pp. 1981-2030 (1995)	
	BI	Goldstein, et al.; "Hyperlipidemia in Coronary Heart Disease"; J. Clin. Invest., 52:1533-1543 (1973)	
	BJ	Gura, et al.; "Obesity Sheds its Secrets"; Science, 275:751-753; Feb. 7, 1997	
	BK	Hayward, et al.; "The cDNA Sequence of Human Endothelial Cell Multimerin"; J. Biol. Chem., 270:18246-18251 (1995)	
	BL	Henrion, et al.; "Structure, Sequence, and Chromosomal Location of the Gene for USF2 Transcription Factors in Mouse", Genomics, 25:36-43 (1995)	
	BM	Herz, J., et al.; "Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-Receptor suggest a physiological role as lipoprotein receptor"; European Molecular Biology Laboratory, 7:4119-4127 (1988)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/072.159
		Filing Date	February 5, 2002
		First Named Inventor	Bernard BIHAIN, et al.
		Group Art Unit	1656
		Examiner Name	Unassigned
		Attorney Docket Number	29.US4.DIV
Sheet	7	of	10

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	BN	Honore, B., et al.; "Cloning and expression of a cDNA covering the complete coding region of the P32 submit of human pre-mRNA splicing factor SF2"; Gene, 134:283-287 (1993)	
	BO	Hu, et al.; "AdipoQ is a Novel Adipose-specific Gene Dysregulated in Obesity"; J. Biol. Chem., 271:10697-10703 (1996)	
	BP	Huettinger, M., et al.; "Characteristics of Chylomicron Remnant Uptake into Rat Liver"; Clin. Biochem., 21:87-92 (1988)	
	BQ	Huto, et al.; "AdipoQ is a Novel Adipose-specific Gene Dysregulated in Obesity"; Jr. of Biol. Chem., 271, 18:10697-10703 (1997)	
	BR	Karpe, F., et al.; "Clearance of lipoprotein remnant particles in adipose tissue and muscle in humans"; J. Lipid Res. 38:2335-2343 (1997)	
	BS	Karpe, F., et al.; "Magnitude of alimentary lipemia is related to intima-media thickness of the common carotid artery in middle-aged men"; Elsevier Science Ireland; 141:307-314 (1998)	
	BT	Khaliou, et al.; "Correction of delayed postprandial plasma lipid response in genetically obese mice by injection of recombinant leptin"; Abstract from the 69th Scientific Sessions, New Orleans, LA; Supplemental to Circulation, American Heart Assoc., Vol. 94:8 (1996)	
	BU	Krainer, A.R., et al.; "Functional expression of cloned human splicing factor SF2: Homology to RNA-binding proteins, U1 70K, and drosophila splicing regulators"; Cell, 66:383-394 (1991)	
	BV	Lee, M.G-S, et al.; "Characterization of cDNA encoding a cystein-rich cell surface protein located in the Flagellar pocket of the protozoan Trypanosoma Brucei"; Molec. Cell. Biol., 10:4506-4517 (1990)	
	BW	Letourneur, F., et al.; "A novel Di-Leucine motif and a Tyrosine-based Motif independently mediate Lysosomal targeting and Endocytosis of CD3 chains"; Cell, 69:1143-1157 (1992)	
	BX	Lewis, G.F., et al.; "Postprandial lipoprotein metabolism in normal and obese subjects: comparison after the Vitamin A fat-loading test"; Jr. of Clinic. Endo.; 71:1041-1050 (1990)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/072.159		
		Filing Date	February 5, 2002		
		First Named Inventor	Bernard BIHAIN, et al.		
		Group Art Unit	1656		
		Examiner Name	Unassigned		
Sheet	8	of	10	Attorney Docket Number	29.US4.DIV

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	BY	Lin, et al.; "Archaic Structure of the Gene Encoding Transcription Factor USF"; Jr. of Bio. Chem., 269:23894-23903 (1994)	
	BZ	Liu, Q., et al.; "Design of polydactyl zinc-finger proteins for unique addressing within complex genomes"; Proc. Natl. Acad. Sci. USA; 94:5525-5530 (1997)	
	CA	Maeda, et al.; "cDNA Cloning and expression of a novel adipose specific collagen-like factor, apM1 (Adipose most abundant gene transcript 1)"; Biochem. and Biophys. Research Comm., 221:286-289 (1996)	
	CB	Mahley, R.W., et al.; "Type III hyperlipoproteinemia (Dysbetalipoproteinemia): The role of Apolipoprotein E in normal and abnormal lipoprotein metabolism"; The Molecular Basis of Inherited Disease, eds. Scriver, et al., McGraw Hill Inc., New York; pp. 1953-1980 (1995)	
	CD	Mann, C.J., et al.; "ApoCIII inhibits the binding of Triglyceride-rich lipoproteins to the lipolysis stimulated receptor"; Abstract (1996)	
	CE	Massie, et al.; "Inducible overexpression of a toxic protein by an Adenovirus vector with a Tetracycline-regulatable expression cassette"; Journal of Virology, 72:2289-2296 (1998)	
	CF	Montague, et al.; "congenital leptin deficiency is associated with severe early-onset obesity in humans"; Nature, 387:903-908 (1997)	
	CG	Parra-Lopez, C.A., et al.; "Presentation on Class II MHC molecules of endogenous Lysozyme targeted to the Endocytic pathway"; J. Immunol.; 158:2670-2679 (1997)	
	CH	Pengue, G., et al.; "Repression of transcriptional activity at a distance by the evolutionarily conserved KRAB domain present in a subfamily of zinc finger proteins"; Nucleic Acids Research, Vol. 22, No. 15, 2908-2914 (1994)	
	CI	Rajput-Williams, J., et al.; "Variation of Apolipoprotein-B gene is associated with obesity, high blood cholesterol levels, and increased risk of coronary heart disease"; The Lancet, pp. 1442-1446 (1988)	
	CJ	Rutherford, S., et al.; "Association of a low density lipoprotein receptor micro-satellite variant with obesity"; Intl. Jr. of Obesity; 21:1032-1037 (1997)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/072.159
		Filing Date	February 5, 2002
		First Named Inventor	Bernard BIHAIN, et al.
		Group Art Unit	1656
		Examiner Name	Unassigned
		Attorney Docket Number	29.US4.DIV
Sheet	9	of	10

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CK	Schaffler, et al.; "Identification and characterization of the human adipocyte apM-1 promoter"; Biochem and Biophys Res. Comm.; 1399:187-197 (1998)	
	CL	Scherer, et al.; "A novel serum protein similar to Clq, produced exclusively in Adipocytes"; J.Biol. Chem.; 270:26746-26749 (1995)	
	CM	Sellar, et al.; "Characterization and organization of the genes encoding the A-, B- and C-chains of human complement subcomponent Clq"; Biochemical Journal, 274:418-190 (1991)	
	CN	Shimabukuro, M., et al.; "Direct antidiabetic effect of leptin through triglyceride depletion of tissues"; Proc. Natl. Acad. Sci. USA; 94:4637-4641 (1997)	
	CO	Shimano, H., et al.; "Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a"; J. Clin. Invest.; 98:1575-1584 (1996)	
	CP	Shin, J., et al.; "Phosphorylation-dependent down-modulation of CD4 requires a specific structure within the cytoplasmic domain of CD4"; Jr. of Biol. Chem.; Vol. 266:10658-10665 (1991)	
	CQ	Simos, G., et al.; "The lamin B receptor-associated protein p34 shares sequence homology and antigenic determinants with the splicing factor 2-associated protein p32"; FEBS Letters 346:225-228 (1994)	
	CR	Steingrimsson, E., et al.; "Murine chromosomal location of five bHLH-Zip transcription factor genes"; Genomics, 28:179-183 (1995)	
	CS	Troussard, A.A., et al.; "Inhibitory effect on the lipolysis-stimulated receptor of the 39-kDa receptor-associated protein"; Jr. of Biol. Chem.; 270:17068-71 (1995)	
	CT	Urade, Y., et al.; "Precerebellin is a cerebellum-specific protein with similarity to the globular domain of complement Clq B chain"; Proc. Natl. Sci. USA; 88:1069-1073 (1991)	
	CU	Van den Berg, R.H., et al.; "Intracellular localization of the human receptor for the globular domains of Clq"; American Association of Immunologists; 158:3909-3916 (1997)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
		Application Number	10/072.159
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Filing Date	February 5, 2002
		First Named Inventor	Bernard BIHAIN, et al.
		Group Art Unit	1656
		Examiner Name	Unassigned
		Attorney Docket Number	29.US4.DIV
Sheet	10	of	10

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	CV	Verhey, K.J., et al.; "A Leu-Leu sequence is essential for COOH-terminal targeting signal of GLUT4 glucose transporter in fibroblasts"; J. Biol. Chem.; 269:2353-2356 (1994)	
	CW	Wang, et al.; "Upstream stimulatory factor binding to the E-box at -65 is required for insulin regulation of the fatty acid synthase promoter"; J. Biol. Chem.; 272:26367-26374 (1997)	
	CX	Yen, F.T., et al.; "Identification of a lipolysis-stimulated receptor that is distinct from the LDL receptor and the LDL receptor-related protein"; Biochemistry; 33:1172-1180 (1994)	
	CY	Zhang, M., et al.; "Tumor necrosis factor"; The Cytokine Handbook; Third Ed., pp. 517-548 (1998)	
	CZ	Zhong, G., et al.; Related leucine-based cytoplasmic targeting signals in invariant chain and major histocompatibility complex Class II molecules acontrol endocytic presentation of distinct determinants in a single protein"; J. Exp. Med.; 185:429-438 (1997)	
	DA	Mann, C.J., et al.; "ApoCIII inhibits the binding of Triglyceride-Rich Lipoproteins to the Lipolysis Stimulated Receptor"; Abstract (1996)	
	DB	Das, K., et al.; "Chromosomal localizations, expression pattern, and promoter analysis of the mouse gene encoding adipocyte-specific secretory protein ACRP30"; Biochemical and Biophysical Research Communications, 2001, 280:1120-1129; Academic Press [available online at http://www.idealibrary.com]	
	DC	Nakano, Y., et al.; "Isolation and Characterization of GBP28, a Novel Gelatin-Binding Protein Purified from Human Plasma"; J. Biochem., 1996, 120(4):803-812	
	DD	Woodward, F.P., et al.; "Characterization and purification of the lipolysis-stimulated receptor"; Atherosclerosis X; 1995, 465-70; Elsevier Science, Amsterdam NL; XP002067569	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.